Hostname: page-component-7d684dbfc8-lxvtp Total loading time: 0 Render date: 2023-10-02T04:08:02.228Z Has data issue: false Feature Flags: { "corePageComponentGetUserInfoFromSharedSession": true, "coreDisableEcommerce": false, "coreDisableSocialShare": false, "coreDisableEcommerceForArticlePurchase": false, "coreDisableEcommerceForBookPurchase": false, "coreDisableEcommerceForElementPurchase": false, "coreUseNewShare": true, "useRatesEcommerce": true } hasContentIssue false

Targeted vaccination with meningococcal polysaccharide vaccine in one district of the Czech Republic

Published online by Cambridge University Press:  15 May 2009

P. Kriz
National Reference Laboratory for Meningococcal Infections, National Institute of Public Health, Srobarova 48, 100 42 Prague 10, Czech Republic
J. Vlckova
District Institute of Hygiene, Olomouc, Czech Republic
M. Bobak
Department of Epidemiology and Population Sciences, London School of Hygiene and Tropical Medicine, London, UK
Rights & Permissions [Opens in a new window]


Core share and HTML view are not possible as this article does not have html content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Vaccination against Neisseria meningitidis is not part of routine immunization schemes in any country; instead, targeted vaccination of groups at the highest risk is recommended during outbreaks and epidemics. After a long period of sporadic occurrence of meningococcal invasive disease, a new clone of Neisseria meningitidis C: 2a: P1.2, ET-15/37, occurred in the Czech Republic, and caused local outbreaks in two neighbouring districts, Olomouc and Bruntal, in spring 1993. In Olomouc, a mass campaign was conducted during which 6191 students were vaccinated (5·6 % of the total population of this locality and 96% of all students in the age group 15–19) within 2 weeks in June 1993. In Bruntal district, no such campaign was organized. In Olomouc, the incidence of invasive disease caused by Neisseria meningitidis C in the age group 10–24 decreased from 57 to 0 per 100000 (P < 0·001) during the post-vaccination period (July 1993–August 1994), but no such decrease was observed in Bruntal. Although other factors can affect the frequency of disease, these results support the current recommendations of targeted vaccination in outbreaks of meningococcal disease.

Research Article
Copyright © Cambridge University Press 1995


1.Bohr, V, Hansen, BO, Kjersem, H et al. , Sequelae from bacterial meningitis and their relation to the clinical condition during acute illness, based on 667 questionnaire returns. J Infect 1983; 7: 102–10.CrossRefGoogle ScholarPubMed
2.Greenwood, BM, Bradley, AK, Smith, AW, Wall, RA. Mortality from meningococcal disease during an epidemic in the Gambia, West Africa. Trans R Soc Trop Med Hyg 1987; 81: 536–8.CrossRefGoogle ScholarPubMed
3.Halstensen, A, Pedersen, SHJ, Haneberg, B et al. , Case fatality of meningococcal disease in western Norway. Scand J Infect Bis 1987; 19: 3542.CrossRefGoogle ScholarPubMed
4.Cartwright, KAV, Stuart, M, Noah, ND. An outbreak of meningococcal disease in Gloucestershire. Lancet 1986; ii: 558–61.CrossRefGoogle Scholar
5.Rønne, T, Lind, I, Buhl, LH, Poolman, JT, Zoffmann, H. Recurrent localized outbreaks of group C meningococcal disease and selective vaccination programmes. Anton Leeuwenhoek J Microbiol Serol 1986; 52: 221–2.CrossRefGoogle Scholar
6.Ashton, FE, Ryan, A, Borczyk, AL, Caugant, DA, Mancino, L, Huang, D. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J Clin Microbiol 1991; 29: 2489–93.Google Scholar
7.Whalen, CM, Hockin, JC, Ryan, A, Ashton, F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA 1995; 273: 390–4.CrossRefGoogle ScholarPubMed
8.Jackson, LA, Schuchat, A, Reevers, MW, Wenger, JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995; 273: 383–9.CrossRefGoogle ScholarPubMed
9.Branham, SE. Serological relationship among meningococci. Bacterial Rev 1953; 17: 175–88.Google Scholar
10.Branham, SE. Reference strains for the serologie groups of meningococcus. Int Bull Bact Nomencl Taxon 1958; 8: 115.Google Scholar
11.Slaterus, KW. Serological typing of meningococci by means of micro-precipitation: Anton Leeuwenhoek J Microbiol Serol 1961; 27: 304–15.Google ScholarPubMed
12.Evans, JR, Artenstein, MS, Hunter, DH. Prevalence of meningococcal serogroups and description of three new groups. Am J Epidemiol 1968; 87: 643–6.CrossRefGoogle ScholarPubMed
13.Ding, SQ, Ye, RB, Zhang, HC. Three new serogroups of Neisseria meningitidis. J Biol Stand 1981; 9: 307–15.CrossRefGoogle ScholarPubMed
14.Ashton, FE, Ryan, A, Diena, B, Jennings, HJ. A new serogroup L of Neisseria meningitidis. J Clin Microbiol 1983; 17: 722–7.Google ScholarPubMed
15.Grahlow, WD, Kuzemenska, P. Meningitis in a child due to Neisseria meningitidis group K. Infection 1989; 17: 309–10.CrossRefGoogle Scholar
16.Frasch, CE, Zollinger, WD, Poolman, JT. Serotype antigens of Neisseria meningitidis and proposed scheme for designation of serotypes. Rev Infect Dis 1985; 7: 504–10.CrossRefGoogle ScholarPubMed
17.Abdillahi, H, Poolman, JT. Definition of meningococcal class I OMP subtype antigens by monoclonal antibodies. FEMS Microbiol Immunol 1988; 47: 139–44.CrossRefGoogle Scholar
18.Ceesay, SJ, Allen, SJ, Menon, A et al. , Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infect Dis 1993; 167: 1212–6.CrossRefGoogle ScholarPubMed
19.Käyhty, H, Karanko, V, Peltola, H, Sarna, S, Mäkela, PH. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J Infect Dis 1980; 142: 861–8.CrossRefGoogle Scholar
20.Gold, R, Lepow, ML, Goldschneider, I, Gotschlich, EC. Immune response of human infants to polysaccharide vaccines of groups A and C Neisseria meningitidis. J Infect Dis 1977; 136: 831–5.CrossRefGoogle Scholar
21.Lepow, ML, Goldschneider, I, Gold, R, Randolph, M, Gotschlich, EC. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 1977; 60: 673–80.Google ScholarPubMed
22.Peltola, H, Mäkela, PH, Käyhty, H et al. , Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. New Engl J Med 1977; 297: 686–91.CrossRefGoogle Scholar
23.Reingold, AL, Broome, CV, Hightower, AW et al. , Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; ii: 114–18.CrossRefGoogle Scholar
24.WHO Study Group. Cerebrospinal meningitis control. WHO Tech Rep 1976; Ser 588: 822.Google Scholar
25.Public Health Advisory Committee on Immunization Practices: Meningococcal polysaccharide vaccines. MMWR 1975; 24: 381–2.Google Scholar
26.Mäkela, PH, Käyhty, H, Weckstrom, P et al. , Effects of group A meningococcal vaccine in army recruits in Finland. Lancet 1975; ii: 883–6.CrossRefGoogle Scholar
27.Stroffolini, T. Vaccination campaign against meningococcal disease in army recruits in Italy. Epidemiol Infect 1990; 105: 579–83.CrossRefGoogle ScholarPubMed
28.Greenwood, BM, Wali, SS. Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet 1980; i: 729–32.CrossRefGoogle Scholar
29.Greenwood, BM, Smith, AW, Hassan-King, M et al. , Theefficacyof meningococcal polysaccharide vaccine in preventing group A meningococcal disease in the Gambia, West Africa. Trans R Soc Trop Med Hyg 1986; 80: 106–7.CrossRefGoogle Scholar
30.Mäkela, PH, Peltola, H, Käyhty, H et al. , Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 1977; 136 (suppl.): S43–S50.CrossRefGoogle Scholar
31.Moore, PS, Toole, MJ, Nieburg, P, Waldman, RJ, Broome, CV. Surveillance and control of meningococcal meningitis epidemics in refugee populations. Bull WHO 1990; 68: 587–96.Google ScholarPubMed
32.Peltola, H. Group A meningococcal polysaccharide vaccine and course of the group A meningococcal epidemic in Finland. Scand J Infect Dis 1978; 10: 41–4.CrossRefGoogle Scholar
33.Rønne, T, Berthelsen, L, Buhl, LH, Lind, I. Comparative studies on pharyngeal carriage of Neisseria meningitidis during a localized outbreak of serogroup C meningococcal disease. Scand J Infect Dis 1993; 25: 331–9.CrossRefGoogle ScholarPubMed
34.Kuzemenska, P, Kriz, B. Epidemiology of meningococcal disease in Central and Eastern Europe. In Vedros, NA, ed. Evolution of meningococcal disease, vol I. Boca Raton, Florida: CRC Press, Inc, 1987: 103–37.Google Scholar
35.Kriz-Kuzemenska, P, Benes, C, Dlhy, J et al. , Increased incidence of invasive meningococcal disease in some regions in the Czech Republic caused by meningococcus C:2a:P1.2. Cs Epidemiol 1993; 42: 165–71.Google Scholar
36.Kriz, P, Musilek, M, Lebedova, V. New epidemiological situation in the Czech Republic caused by meningococcus C:2a:Pl.2(P1.5). Epidemiol Microbiol Immunol 1994; 43: 183–7.Google Scholar
37.Roznovsky, L, Matuska, J, Kriz-Kuzemenska, P. Unusual incidence of serious meningococcal diseases in some north Moravian districts in the first half of 1993. Prakt lek 1994; 74: 101–4.Google Scholar
38.Selander, RK, Caugant, DA, Ochman, H, Musser, JM, Gilmour, MN, Whitam, TS. Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics. Appl Environ Microbiol 1986; 51: 873–84.Google ScholarPubMed
39.Caugant, DA, Frøholm, LO, Bovre, K et al. , Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc Natl Acad Sci 1986; 83: 4927–31.CrossRefGoogle ScholarPubMed
40.Kirkwood, BR. Essentials of medical statistics. Oxford: Blackwell Scientific Publications, 1988.Google Scholar
41. EGRET users manual. Seattle: Statistics and Epidemiology Research Corporation, 1988.Google Scholar
42.Cuevas, LE, Hart, CA. Chemoprophylaxis of bacterial meningitis. J Antimicrob Chemother 1993; 31 Suppl B: 7991.CrossRefGoogle ScholarPubMed
43.Lennon, D, Gellin, B, Hood, D, Voss, L, Heffernan, H, Thakur, S. Successful intervention in a group A meningococcal outbreak in Auckland, New Zealand. Pediatr Infect Dis J 1992; 11: 617–23.Google Scholar